rethinkTHC Search
Menu
Study breakdown

Anorexia nervosa involves coordinated shutdown of the endocannabinoid system through dual epigenetic changes

Case ControlModerate evidence
The takeaway

People with anorexia nervosa showed simultaneous epigenetic changes that both reduce cannabinoid receptor availability and increase endocannabinoid degradation, creating a coordinated suppression of appetite-regulating signals.

Eating disorder researchers, epigeneticists, psychiatrists, and anyone interested in the molecular basis of anorexia nervosa.

What the researchers found

A novel bidirectional epigenetic dysregulation was discovered: CNR1 (cannabinoid receptor 1) promoter hypermethylation coupled with FAAH (endocannabinoid-degrading enzyme) promoter hypomethylation. This creates a dual mechanism that systematically suppresses endocannabinoid signaling by reducing receptors while increasing signal degradation.

Why it matters

This identifies a specific molecular mechanism for appetite dysregulation in anorexia nervosa. The finding that both the receptor and the degradation enzyme are epigenetically altered in coordinated fashion suggests a systemic rather than incidental disruption of appetite signaling.

The numbers in context

CNR1 promoter hypermethylated (reduced receptor). FAAH promoter hypomethylated (increased degradation). Compensatory miRNA responses detected. Combined biomarker panels showed superior diagnostic precision vs. individual markers.

How the study worked

Case-control study analyzing DNA methylation of CNR1 and FAAH genes, genetic polymorphisms, and exosomal microRNA expression in saliva samples from anorexia nervosa patients versus healthy controls.

What this study cannot tell us

Saliva-based measurements may not directly reflect brain ECS function. Cannot determine if epigenetic changes cause or result from the disorder. Sample sizes not specified in abstract. Case-control design limits temporal inference.

How to read the evidence

Novel mechanistic finding with integrated epigenetic, genetic, and miRNA analysis, though limited by case-control design and saliva-based measurements.

When this study was published

2025 publication.

The bigger picture

Anorexia nervosa has few biomarkers and limited understanding of its molecular basis. The endocannabinoid system, known for regulating appetite and reward, appears to be systematically suppressed through coordinated epigenetic changes, opening potential diagnostic and therapeutic avenues.

Questions still open

  • Could drugs that reverse FAAH hypomethylation or CNR1 hypermethylation be therapeutic for anorexia nervosa?
  • Do these epigenetic changes normalize with weight restoration and recovery?

Common questions

How does the endocannabinoid system regulate appetite?
The endocannabinoid system, particularly through CB1 receptors, promotes appetite and food reward. Anandamide (an endocannabinoid) stimulates hunger signals. When receptors are reduced and anandamide is broken down faster, appetite signaling is suppressed.
Could these findings lead to treatments for anorexia?
Potentially. If the epigenetic changes driving ECS suppression are reversible, they could be therapeutic targets. The combined biomarker panel also showed diagnostic promise, which could help identify and monitor the condition.

Read the original research

Coordinated epigenetic dysregulation of CNR1 and FAAH genes drives endocannabinoid system dysfunction in anorexia nervosa.

Journal of eating disorders, 14(1), 5

Citation

Gilardini, Federica; Mercante, Francesca; Sabatucci, Annalaura; Pucci, Mariangela; Cifani, Carlo; Segura-Garcia, Cristina; Rania, Marianna; D'Addario, Claudio. (2025). Coordinated epigenetic dysregulation of CNR1 and FAAH genes drives endocannabinoid system dysfunction in anorexia nervosa.. Journal of eating disorders, 14(1), 5. https://doi.org/10.1186/s40337-025-01472-y

Explore the wider topic